Sheng et al. (2015) conducted a meta-analysis including 26 studies and showed that patients with NSCLC and EGFR exon 19 deletion had a longer PFS, OS, and higher ORR compared with exon 21 L858R mutation after EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.